Neuromyelitis optica (NMO), also known as Devic’s syndrome, is a rare autoimmune demyelinating disease that occurs in the central nervous system, characterized by recurrent inflammation of the optic nerve and spinal cord, often leading to blindness or limb disability, and a poor prognosis. NMO-IgG (also known as AQP4 antibody) is a specific protein expressed in NMO patients and can be used as a reference for clinical diagnosis.
According to the guidelines established by neurologists in 2006, the diagnosis of NMO must be based on at least one clinical episode of optic nerve and myelitis, combined with two of the following three conditions: (1) MRI showing three or more consecutive spinal cord seizures (2) brain MRI does not meet MS diagnostic criteria and (3) positive serum AQP4 antibodies. Since NMO and multiple sclerosis (MS) are similar in clinical manifestations, AQP4 antibody detection can help physicians distinguish between NMO and MS, which is helpful for the identification of unclear clinical features and early diagnosis.
華宇分子生物實驗室
華宇藥品股份有限公司 華宇分子生物實驗室
TAF ISO 17025 認證實驗室
